<DOC>
	<DOCNO>NCT02232646</DOCNO>
	<brief_summary>This open label , multi-center , Phase II study BBI503 administer adult patient select advanced urologic malignancy . The primary objective study evaluate disease control rate patient renal cell cancer urothelial carcinoma treat BBI503 .</brief_summary>
	<brief_title>A Study BBI503 Adult Patients With Advanced Urologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Signed write informed consent Histologically cytologically confirm renal cell cancer urothelial carcinoma metastatic , unresectable , recurrent . ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI503 dose Females childbearing potential must negative serum pregnancy test Alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) , ≤ 3.5 x ULN presence primary metastatic hepatic lesion Hemoglobin ( Hgb ) ≥ 10 g/dl Total bilirubin ≤ 1.5 x ULN Creatinine ≤ 1.5 x ULN creatinine clearance &gt; 50 mL/min/1.73 m^2 patient creatinine level institutional normal . Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Prothrombin time ( PT ) ≤ 16 second partial thromboplastin time ( PTT ) ≤ 1.5 x ULN Life expectancy ≥ 3 month A patient renal cell carcinoma ( RCC ) must classify clearcell nonclear cell subtype , must meet following criterion : Patients clear cell renal cancer must receive prior treatment least one line standard systemic therapy include treatment tyrosine kinase inhibitor ; either alone combination . The patient must either progressive disease treatment , document intolerance first line tyrosine kinase inhibitor ( TKI ) base therapy . Patients clear cell renal cancer receive anticancer treatment beyond firstline TKIbased therapy may enroll . Patients clear cell renal cancer receive anticancer treatment beyond firstline TKIbased therapy may enroll discuss potential risk benefit alternative treatment option , currently available agent approve treatment patient clear cell renal cancer . Patients nonclear cell RCC metastatic may enroll without received prior treatment metastatic set A patient urothelial carcinoma must also meet follow criterion : Must receive least one prior line standard systemic cytotoxic therapy metastatic setting . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI503 . Patients may begin BBI503 date determine investigator medical monitor sponsor provide minimum 7 day since last receiving anticancer treatment , prior treatmentrelated adverse event ( AEs ) resolve deem irreversible . Major surgery within 4 week prior first dose ( require general anesthesia and/or inpatient hospitalization recovery ) . Any known symptomatic untreated brain metastasis require increase steroid dose within 2 week prior start study . Patients treat brain metastasis must stable 4 week completion treatment . Posttreatment image documentation stability require within 4 month start study . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . Pregnant breastfeeding Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) Unable unwilling swallow BBI503 capsule daily Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement ( e.g . reliable transportation ) . Patients history malignancy tumor interest except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease &gt; 3 year . Abnormal ECGs clinically significant QT prolongation QTc &gt; 480 msec , clinically significant cardiac enlargement hypertrophy , new bundle branch block , sign active ischemia . Patients evidence prior infarction New York Heart Association ( NYHA ) functional class II , III , IV exclude , patient mark arrhythmia Wolff Parkinson White pattern complete atrioventricular ( AV ) dissociation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>